KemPharm Inc. (KMPH)’s Financial Results Comparing With Evelo Biosciences Inc. (NASDAQ:EVLO)

As Biotechnology businesses, KemPharm Inc. (NASDAQ:KMPH) and Evelo Biosciences Inc. (NASDAQ:EVLO), are affected by compare. This especially applies to their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
KemPharm Inc. 2 0.00 N/A -2.26 0.00
Evelo Biosciences Inc. 8 0.00 N/A -2.14 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for KemPharm Inc. and Evelo Biosciences Inc.


Table 2 provides KemPharm Inc. and Evelo Biosciences Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
KemPharm Inc. 0.00% 53.1% -171.3%
Evelo Biosciences Inc. 0.00% -47.8% -41%


1 and 1 are the respective Current Ratio and a Quick Ratio of KemPharm Inc. Its rival Evelo Biosciences Inc.’s Current and Quick Ratios are 11.9 and 11.9 respectively. Evelo Biosciences Inc. has a better chance of clearing its pay short and long-term debts than KemPharm Inc.

Insider & Institutional Ownership

KemPharm Inc. and Evelo Biosciences Inc. has shares held by institutional investors as follows: 33.5% and 86.1%. About 0.5% of KemPharm Inc.’s share are held by insiders. On the other hand, insiders held about 2.68% of Evelo Biosciences Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
KemPharm Inc. -9.35% -25.44% -8.7% -53.85% -67.69% -29.21%
Evelo Biosciences Inc. -18.64% -30.57% -28.12% -33.8% -51.66% -53.04%

For the past year KemPharm Inc.’s stock price has smaller decline than Evelo Biosciences Inc.


Evelo Biosciences Inc. beats on 4 of the 6 factors KemPharm Inc.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. The company is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. KemPharm, Inc. was founded in 2006 and is headquartered in Coralville, Iowa.

Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.